Oxbridge Clinical

Oxbridge Clinical’s AI-powered sensor diagnoses infections in 10 minutes, anywhere—no lab, no reagents/preprocessing, 1/100th PCR cost. Backed by Barilla, we’re redefining diagnostics and food safety.

We raised a $1M pre-seed round from the family office of Guido Barilla, President of the Barilla Group—World’s largest pasta producer, $5B in revenue, present in 100+ countries, 140 production units. We validated our tech with >99% accuracy across multiple pathogens. We filed broad-scoped patents to USPTO—now undergoing PCT internationalization. We’re now raising a $4.5M seed round ($1M committed) to automate the platform, launch pilots, and enter the food safety market—our first revenue stream—within 18 months, while advancing clinical regulatory pathways in parallel.

Primary care doctors lack tools to identify the cause of infections, forcing them to prescribe antibiotics blindly. >3/4 infectious disease patients walk home with inappropriate therapies, leading to billions spent in (avoidable) hospitalizations, and fueling antimicrobial resistance crisis (bound to become the #1 cause of death). Meanwhile, food manufacturers have no tools to detect microbial contamination quickly, as the fastest tests take 1 day: they are often forced to send out food batches WHILE they perform these tests, exposing them to the risk of recalls—costing tens of millions each.

We have developed an ultra-low-cost, pocket-sized diagnostic platform that detects dozens of bacteria, viruses and fungi—all while requiring no lab, no molecular reagents, no temperature sensitive parts. Our patented technology combines solid-state micropores with a state-of-the-art AI engine. We can quantitatively detect microorganisms from any raw sample in >99% accuracy, and assess antibiotic resistance in 2-3 hours. It’s a plug-and-play solution that brings lab-grade diagnostics to the field, clinic, or factory floor—at 1/100th the cost of PCR!

We will use a razor-and-blade model. The sensor (~$2–3K) is sold at cost, while recurring revenue comes from consumables ($20-50/test). For clinical markets, we will perform a clincial trial (already designed), file an FDA de novo application, pursue CPT III and CPT I. Physicians will be incentivized to use our device based on our partnership with Accountable Care Organizations (ACOs). For food markets, we will pursue ISO 9001:2015 and AOAC PTM clearance, and sell it as a subscription (SaaS-like). Our financial forecasts, using conservative assumptions, project a >$100M revenue in 5 years.

1) EnterpriseTECH STAR (Judge Business School, University of Cambridge) – selection of 14 start-up projects across the University of Cambridge for a 3mo non-dilutive accelerator; ranked #1 in our cohort.
2) Accelerate Cambridge (Judge Business School, University of Cambridge) – 3mo non-dilutive accelerator; ranked #1 in our cohort.
3) Finalist, Trinity Bradfield Prize, University of Cambridge.
4) MedTech Innovator, BioTools Innovator Program + BARDA Vanguard track (10 selected among 420 applicants, 2% selection rate) – 6-mo non-dilutive accelerator.